PTGX,Protagonist Therapeutics, Inc. | Healthcare

Healthcare

PTGX

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

Protagonist Therapeutics, Inc.PTGX

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

% Change

Description >

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases.

It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of erythrocytosis, iron overload, and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that is in Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist, which is in Phase II clinical trials for inflammatory bowel disease.

The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Latest News >

Wealthspire’s Fiducient Advisors Acquires Axia Advisory

Apr 7, 2026

$1.9 billion retirement plan consultant in Indianapolis joins growing national platform NEW YORK--(BUSINESS WIRE)-- Wealthspire, an independent wealth management, institutional advisory, and business management firm, today announced that Fiducient Advisors has completed its acquisition of Axia Advisory, an Indianapolis-based retirement plan consulting and investment advisory firm with $1.9 billion in assets under management or advisement.* The addition of Axia...

North American Construction Group Closes Strategic Acquisition of Iron Mine Contracting, a Diversified Mining Services Contractor

Apr 7, 2026

ACHESON, Alberta, April 07, 2026 (GLOBE NEWSWIRE) -- North American Construction Group Ltd. ( NOA ) (“NACG” or the “Company”) today announced the closing of its acquisition of Iron Mine Contracting (“IMC”), with a closing date of April 7, 2026 and an economic effective date of January 1, 2026 (the “Transaction”). Total expected consideration is approximately $125 million (the “Consideration”),...

Caturus' Wellhead-to-Water Strategy Achieves Major Milestones in Upstream and LNG Development

Apr 7, 2026

Commonwealth LNG Project achieves full commerciality Project financing process imminent for $12.5 billion LNG project Pre-FID site objectives progressing with EPC partner Technip Energies Pending $950 million acquisition of SM Energy assets remains on track HOUSTON, April 7, 2026 /PRNewswire/ -- Caturus announced today its Commonwealth LNG project has finalized customer offtake agreements to underpin financing of its LNG facility in...

Booz Allen Completes Acquisition of Defy Security

Apr 7, 2026

Accelerating Advanced Cybersecurity for New Age of Enterprise Threats MCLEAN, Va.--(BUSINESS WIRE)-- Booz Allen Hamilton ( BAH ) today announced it has completed its acquisition of Defy Security. The transaction was previously announced on February 17, 2026. Defy provides cybersecurity technology products and services to leading financial services, healthcare, manufacturing, and retail enterprises. Combining its robust customer base, sales infrastructure,...